在巴瑞替尼治疗抵抗的特应性皮炎中使用托法替尼：JAK 抑制剂转换的一个实例。
Use of tofacitinib in baricitinib-refractory atopic dermatitis: An example of JAK inhibitor switching.
机构信息
Department of Dermatology, Venereology and Leprosy, Atal Bihari Vajpayee Institute of Medical Sciences and Research Institute and Dr Ram Manohar Lohia Hospital, New Delhi, India.
出版信息
Pediatr Dermatol. 2024 Jan-Feb;41(1):139-140. doi: 10.1111/pde.15386. Epub 2023 Jul 26.
Atopic dermatitis (AD) is predominantly mediated by a T-helper 2 immune system response. While JAK inhibitors have gained treatment approval for AD, data regarding interclass efficacy and therapeutic rationale is lacking. We report a patient with recalcitrant AD who failed baricitinib but demonstrated an excellent response to the pan-JAK inhibitor tofacitinib.
特应性皮炎（AD）主要由辅助性 T 细胞 2 免疫应答介导。虽然 JAK 抑制剂已获得 AD 的治疗批准，但关于其疗效和治疗原理的信息仍缺乏。我们报告了 1 例难治性 AD 患者，该患者使用巴瑞替尼治疗无效，但对泛 JAK 抑制剂托法替布反应良好。
Zotero 插件